C. Difficile Nucleic Acid Amplification Test Assay
OMN is the FDA product code for C. Difficile Nucleic Acid Amplification Test Assay, a class I device type, regulated under 21 CFR 866.2660. FDA's definition for this code reads: "In vitro diagnostic test for the qualitative detection of toxigenic clostridium difficile nucleic acids isolated and purified from stool specimens obtained from symptomatic patients". As of , FDA records hold 5 510(k) clearances under this code, the most recent dated , and 2 recalls.
Classification record
- Product code
- OMN
- Device name
- C. Difficile Nucleic Acid Amplification Test Assay
- FDA definition
- In vitro diagnostic test for the qualitative detection of toxigenic clostridium difficile nucleic acids isolated and purified from stool specimens obtained from symptomatic patients.
- Regulation
- 21 CFR 866.2660
- Device class
- Class I
- Review panel
- Microbiology
- Submission type
- 510(k) exempt
- Implant
- No
- Life sustaining or supporting
- No
- GMP exempt
- No
- Third party review eligible
- No
- Ingested clearances
- 5
- Ingested recalls
- 2
Clearances, product code OMN
By decision yearShow the numbers
| Year | Clearances |
|---|---|
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
Applicants with the most clearances
Product code OMN| Applicant | Clearances |
|---|---|
| Meridian Bioscience Inc | 2 |
| Cepheid | 1 |
| DiaSorin Molecular LLC | 1 |
| Great Basin Scientific, Inc. | 1 |
Companies listing this code with FDA
Companies whose registered establishments list this codeFIRST ARTICLE / WEEKLY
What cleared, what was recalled, and what changed in the standards. One edition a week for the people who make medical devices.
